Magnesium citrate with sodium picosulfate
Brand names: Picolax, CitraFleet
This fixed combination of magnesium citrate with sodium picosulfate is a dual-action oral bowel-cleansing preparation taken before colonoscopy, surgery or radiological investigation of the colon.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Sodium picosulfate is a stimulant laxative activated by colonic bacteria to directly stimulate the mucosa and increase motility, while magnesium citrate provides an osmotic effect that retains water in the lumen; together they produce a thorough purge.
Prescribing in practice
- As with all bowel-cleansing agents it carries a real risk of dehydration and electrolyte disturbance, so it is contraindicated in gut obstruction or perforation, ileus, toxic colitis and severe dehydration, and the magnesium component warrants caution in renal impairment.
- Generous clear-fluid intake during cleansing is essential, with particular care in elderly, frail or cardiac patients.
- Because picosulfate requires colonic bacteria for activation, concurrent antibiotics may reduce its effectiveness.
Monitoring
Check or consider renal function and electrolytes before use in at-risk patients, and ensure hydration is maintained throughout the cleansing process.
Counselling the patient
- Take each dose at the times instructed and drink large amounts of clear fluid to stay hydrated.
- Expect watery diarrhoea within hours and stay near a toilet.
- Seek advice if you develop fainting, palpitations, severe pain or persistent vomiting.
Evidence & guidelines
Sodium picosulfate with magnesium citrate is a well-established bowel-preparation regimen in UK endoscopy practice, with safe use guided by attention to hydration and electrolytes.
Reference: NICE; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Corrected Sodium (Hyperglycaemia) · Electrolytes
- Hyponatraemia Cause Algorithm · Electrolyte Disorders
- MELD-Na Score · Liver Disease
- Harvey-Bradshaw Index for Crohn's Disease · Inflammatory Bowel Disease
- Mayo Score for Ulcerative Colitis Activity · Inflammatory Bowel Disease
- Rome IV Criteria for Irritable Bowel Syndrome · Functional GI
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021